Acetyl L-Carnitine (ALCAR, Acetylcarnitine, ALC) is a derivative of the athletic performance supplement Carnitine. Despite their similar names and chemical structures, there is actually a very different mechanism of action for Acetyl L-Carnitine.
This acetylated version of Carnitine offers more mental rather than physical benefits because it is able to cross the blood-brain barrier. Its primary effect is on the production of Acetylcholine.
Acetylcholine is one of the main neurotransmitters involved in memory, learning, computation, analysis, perception and many more cognitive processes.
Elevated Acetylcholine levels can promote increased synaptic plasticity and boost memory formation. Acetyl L-Carnitine works particularly well when stacked with choline supplements and other nootropics that effect the Cholinergic system.



- Increases mental energy & focus
- Promotes neuron health & anti-aging
- Improves memory, alertness & signalling
Acetyl L-Carnitine Effects
Related Topics
Acetyl L-Carnitine has very high bioavailabilty and good transportation across the blood brain barrier (which is what makes it distinct from L-Carnitine).
Once it reaches the brain, ALCAR is broken down into Acetyl-COA which can then bind with choline to form Acetylcholine. The caveat is that there must be sufficient amounts of choline available in order for the Acetylcholine conversion to occur.
For this reason, ALCAR is not considered a direct precursor to Acetylcholine but it is an indirect supplement that contributes to increased levels of this important neurotransmitters.
It is interesting that most of the Acetylcholine supplement users out there only focus on boosting the amount of choline they have in their system and there is less attention paid to the acetate component.
However, by taking an Acetyl L-Carnitine supplement alongside a choline source you may make a dramatic change to Acetylcholine production and activity in the brain.
There are a few other nootropic effects of Acetyl L-Carnitine related to boosting brain health and improving the maintenance of your neurons.
This supplement is a highly effective anti-oxidant which can reduce signs of oxidative stress and remove toxins from the brain. Some experiments have also shown ALCAR to be effective at reducing excitotoxicity which occurs when levels of excitatory neurotransmitters are excessively high.
There is also research pointing to significant neuroprotective properties such as reducing signs of cerebral ischemia and treating nerve and spinal cord injuries. One study in the Annals of Neurology found benefits for using Acetyl L-Carnitine in patients with Parkinson’s disease.
Acetyl L-Carnitine Benefits
What are some of the benefits that you may experience when using this supplement on its own or in a stack? Most Acetyl L-Carnitine benefits revolve around the fact that this compound increases cholinergic activity in the brain.
This increase may lead to better working memory capacity, long-term memory formation, improved recall, heightened reasoning abilities, and increased synaptic plasticity. All of these elements combine to cause improved learning and fluid intelligence.
Many people also notice higher levels of mental energy and better concentration and focus when taking this supplement. You may also feel increased clarity of thought, more alertness, and greater perceptual awareness.
Acetyl L-Carnitine Side Effects & Safety
Acetyl L-Carnitine is a naturally occurring compound that the body can produce on its own in small amounts.
It is considered very safe for almost everyone to take and side effects are rare. In fact, there have not been any recorded cases of dangerous side effects occurring from using or overdosing on Acetyl L-Carnitine.
Some mild side effects may be observed such as headaches, stomach discomfort, nausea, and diarrhea. In rare cases, individuals have reported that this substance produces an unpleasant body odor and bad breath.
If you are pregnant or currently breastfeeding you should avoid this and most other nootropic supplements due to a lack of research on potential effects on unborn and newborn children. It is also advised that individuals with a history of seizures and under active thyroid glands should not take this supplement.
Acetyl L-Carnitine Dosage
The following dosage recommendations are general guidelines only. Speak with your doctor before beginning any new supplements. Your doctor will be able to determine the best dosages for your needs, and also determine if the supplement will negatively interact with any supplements and/or medications you are currently taking.
The average Acetyl L-Carnitine dosage is 500 – 1000 mg taken two to three times a day. This supplement is water soluble and most people say that it works best when taken with food, though this is not necessary.
While ALCAR might have some nootropic effects on its own, the majority of benefits will come from stacking this compound with other brain supplements.
Any cognitive enhancers that work on Acetylcholine pathways will typically synergize well with Acetyl L-Carnitine. It is common to use this supplement with Racetams such as Piracetam, Aniracetam, Pramiracetam and even Noopept.
Of course, the greatest synergies will come from stacking it with Choline sources – especially Choline Bitartrate or Choline Citrate. You can also stack ALCAR with some of the stronger Choline supplements like CDP Choline and Alpha GPC, though you might want to use smaller dosages to prevent headaches from developing.
When used at appropriate dosages and combined with a good choline supplement, Acetyl-L-Carnitine may be a good Acetylcholine boosting supplement, and a great addition to many nootropic stacks.
- Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014
- Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. A review of current evidence for acetyl-l-carnitine in the treatment of depression. J Psychiatr Res. 2014
- Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. Clin Neurol Neurosurg. 2013
- Burotto M, Fojo AT. Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work? Oncologist. 2013
- Campone M, Berton-Rigaud D, Joly-Lobbedez F, Baurain JF, Rolland F, Stenzl A, Fabbro M, van Dijk M, Pinkert J, Schmelter T, de Bont N, Pautier P. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. Oncologist. 2013
- Jiang Q, Jiang G, Shi KQ, Cai H, Wang YX, Zheng MH. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol. 2013
- Onofrj M, Ciccocioppo F, Varanese S, di Muzio A, Calvani M, Chiechio S, Osio M, Thomas A. Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. Expert Rev Neurother. 2013
- Brennan BP, Jensen JE, Hudson JI, Coit CE, Beaulieu A, Pope HG Jr, Renshaw PF, Cohen BM. A placebo-controlled trial of acetyl-L-carnitine and ?-lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol. 2013
- Fernandez IC, Del Carmen Camberos M, Passicot GA, Martucci LC, Cresto JC. Children at risk of diabetes type 1. Treatment with acetyl-L-carnitine plus nicotinamide - case reports. J Pediatr Endocrinol Metab. 2013
- Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013
- Bersani G, Meco G, Denaro A, Liberati D, Colletti C, Nicolai R, Bersani FS, Koverech A. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol. 2013
- Beghi E, Pupillo E, Bonito V, Buzzi P, Caponnetto C, Chiò A, Corbo M, Giannini F, Inghilleri M, Bella VL, Logroscino G, Lorusso L, Lunetta C, Mazzini L, Messina P, Mora G, Perini M, Quadrelli ML, Silani V, Simone IL, Tremolizzo L; Italian ALS Study Group. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013
- Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis. 2013
- Roscilli G, Marra E, Mori F, Di Napoli A, Mancini R, Serlupi-Crescenzi O, Virmani A, Aurisicchio L, Ciliberto G. Carnitines slow down tumor development of colon cancer in the DMH-chemical carcinogenesis mouse model. J Cell Biochem. 2013
- Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathé AA, Pittaluga A, Lionetto L, Simmaco M, Nicoletti F. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A. 2013
- Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2012
- Ren J, Lakoski S, Haller RG, Sherry AD, Malloy CR. Dynamic monitoring of carnitine and acetylcarnitine in the trimethylamine signal after exercise in human skeletal muscle by 7T 1H-MRS. Magn Reson Med. 2013
- Malaguarnera M, Vacante M, Bertino G, Neri S, Malaguarnera M, Gargante MP, Motta M, Lupo L, Chisari G, Bruno CM, Pennisi G, Bella R. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-? 2b plus ribavirin. J Interferon Cytokine Res. 2011
- Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, Nunnari G, Rampello L, Pennisi G. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis. 2011
- Ponte F, Carvalho F, Porto B. Protective effect of acetyl-l-carnitine and ?-lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes. Toxicology. 2011
- Haorah J, Floreani NA, Knipe B, Persidsky Y. Stabilization of superoxide dismutase by acetyl-l-carnitine in human brain endothelium during alcohol exposure: novel protective approach. Free Radic Biol Med. 2011
- Jiang X, Tian Q, Wang Y, Zhou XW, Xie JZ, Wang JZ, Zhu LQ. Acetyl-L-carnitine ameliorates spatial memory deficits induced by inhibition of phosphoinositol-3 kinase and protein kinase C. J Neurochem. 2011
- Mingorance C, Rodríguez-Rodríguez R, Justo ML, Alvarez de Sotomayor M, Herrera MD. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. Vasc Health Risk Manag. 2011
- Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, Pennisi G. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol. 2011
- Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, Ghaleiha A, Akhondzadeh S. Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum Dev. 2011
- Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Malaguarnera M, Li Volti G, Galvano F. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr. 2011
- Martinotti G, Andreoli S, Reina D, Di Nicola M, Ortolani I, Tedeschi D, Fanella F, Pozzi G, Iannoni E, D'Iddio S, Prof LJ. Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011
- Abdul Muneer PM, Alikunju S, Szlachetka AM, Haorah J. Inhibitory effects of alcohol on glucose transport across the blood-brain barrier leads to neurodegeneration: preventive role of acetyl-L: -carnitine. Psychopharmacology (Berl). 2011
- Sinicropi MS, Leone F, Rovito N, Genchi G. Behavior of acetyl-L-carnitine injections (Nicetile fiale) with different drugs used for combined therapy. Adv Ther. 2010
- Martinotti G, Reina D, Di Nicola M, Andreoli S, Tedeschi D, Ortolani I, Pozzi G, Iannoni E, D'Iddio S, Janiri L. Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial. Alcohol Alcohol. 2010
- Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. Clin Cancer Res. 2010
- Ruggenenti P, van der Meer IM, Remuzzi G. Oral acetyl-L-carnitine therapy and insulin resistance. Hypertension. 2010
- Zhang H, Jia H, Liu J, Ao N, Yan B, Shen W, Wang X, Li X, Luo C, Liu J. Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. J Cell Mol Med. 2010
- Genazzani AD, Lanzoni C, Ricchieri F, Santagni S, Rattighieri E, Chierchia E, Monteleone P, Jasonni VM. Acetyl-L-carnitine (ALC) administration positively affects reproductive axis in hypogonadotropic women with functional hypothalamic amenorrhea. J Endocrinol Invest. 2011
- [No authors listed] Acetyl-L-carnitine. Monograph. Altern Med Rev. 2010
- Altun ZS, Güne? D, Akta? S, Erbayraktar Z, Olgun N. Protective effects of acetyl-L-carnitine on cisplatin cytotoxicity and oxidative stress in neuroblastoma. Neurochem Res. 2010
- Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev. 2009
- Ruggenenti P, Cattaneo D, Loriga G, Ledda F, Motterlini N, Gherardi G, Orisio S, Remuzzi G. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension. 2009
- Benedini S, Perseghin G, Terruzzi I, Scifo P, Invernizzi PL, Del Maschio A, Lazzarin A, Luzi L. Effect of L-acetylcarnitine on body composition in HIV-related lipodystrophy. Horm Metab Res. 2009
- Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ. Vitagenes, cellular stress response, and acetylcarnitine: relevance to hormesis. Biofactors. 2009
- Malaguarnera M, Risino C, Cammalleri L, Malaguarnera L, Astuto M, Vecchio I, Rampello L. Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur J Gastroenterol Hepatol. 2009
- Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, Gasimov E, Alvarez LM, Ames BN, Lamanna JC, Aliev G. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci. 2009
- Engle DB, Belisle JA, Gubbels JA, Petrie SE, Hutson PR, Kushner DM, Patankar MS. Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. Gynecol Oncol. 2009
- Cao Y, Wang YX, Liu CJ, Wang LX, Han ZW, Wang CB. Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. Clin Invest Med. 2009
- Janiri L, Martinotti G, Tonioni F, Ghelardini C, Nicolai R, Galeotti N, Mosconi L, Calvani M, Bartolini A, Iannoni E. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome. Clin Neuropharmacol. 2009
- Evans JD, Jacobs TF, Evans EW. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother. 2008
- Epis R, Marcello E, Gardoni F, Longhi A, Calvani M, Iannuccelli M, Cattabeni F, Canonico PL, Di Luca M. Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. Eur J Pharmacol. 2008
- Traina G, Bernardi R, Cataldo E, Macchi M, Durante M, Brunelli M. In the rat brain acetyl-L-carnitine treatment modulates the expression of genes involved in neuronal ceroid lipofuscinosis. Mol Neurobiol. 2008
- Memeo A, Loiero M. Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. Clin Drug Investig. 2008
- Soczynska JK, Kennedy SH, Chow CS, Woldeyohannes HO, Konarski JZ, McIntyre RS. Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? Expert Opin Investig Drugs. 2008
- Arnold LE, Amato A, Bozzolo H, Hollway J, Cook A, Ramadan Y, Crowl L, Zhang D, Thompson S, Testa G, Kliewer V, Wigal T, McBurnett K, Manos M. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2007
- Chan A, Shea TB. Effects of dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4. Neuromolecular Med. 2007
- De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs. 2007
- Chiechio S, Copani A, Gereau RW 4th, Nicoletti F. Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs. 2007
- Sima AA. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs. 2007
- Malaguarnera M, Gargante MP, Cristaldi E, Colonna V, Messano M, Koverech A, Neri S, Vacante M, Cammalleri L, Motta M. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch Gerontol Geriatr. 2008
- Rossini M, Di Munno O, Valentini G, Bianchi G, Biasi G, Cacace E, Malesci D, La Montagna G, Viapiana O, Adami S. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol. 2007
- McMackin CJ, Widlansky ME, Hamburg NM, Huang AL, Weller S, Holbrook M, Gokce N, Hagen TM, Keaney JF Jr, Vita JA. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich). 2007
- Ferraresi R, Troiano L, Roat E, Nemes E, Lugli E, Nasi M, Pinti M, Calvani M, Iannuccelli M, Cossarizza A. Protective effect of acetyl-L-carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett. 2006
- Coleman JK, Kopke RD, Liu J, Ge X, Harper EA, Jones GE, Cater TL, Jackson RL. Pharmacological rescue of noise induced hearing loss using N-acetylcysteine and acetyl-L-carnitine. Hear Res. 2007
- Mancinelli A, D'Iddio S, Bisonni R, Graziano F, Lippe P, Calvani M. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol. 2007
- Pueschel SM. The effect of acetyl-L-carnitine administration on persons with Down syndrome. Res Dev Disabil. 2006
- Osio M, Muscia F, Zampini L, Nascimbene C, Mailland E, Cargnel A, Mariani C. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst. 2006
- Siciliano M, Annicchiarico BE, Lucchese F, Bombardieri G. Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visual-evoked potentials in cirrhotic patients with hepatic encephalopathy. Clin Exp Pharmacol Physiol. 2006
- Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J Nutr Biochem. 2006
- Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology. 2005
- Dhitavat S, Ortiz D, Rogers E, Rivera E, Shea TB. Folate, vitamin E, and acetyl-L-carnitine provide synergistic protection against oxidative stress resulting from exposure of human neuroblastoma cells to amyloid-beta. Brain Res. 2005
- Guideri F, Acampa M, Hayek Y, Zappella M. Effects of acetyl-L-carnitine on cardiac dysautonomia in Rett syndrome: prevention of sudden death? Pediatr Cardiol. 2005
- Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-L-carnitine. Ann N Y Acad Sci. 2005
- Ghirardi O, Lo Giudice P, Pisano C, Vertechy M, Bellucci A, Vesci L, Cundari S, Miloso M, Rigamonti LM, Nicolini G, Zanna C, Carminati P. Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res. 2005
- Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005
- Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori. 2005
- Sima AA, Calvani M, Mehra M, Amato A; Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care. 2005
- Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004
- Kwon OS, Chung YB. HPLC determination and pharmacokinetics of endogenous acetyl-L-carnitine (ALC) in human volunteers orally administered a single dose of ALC. Arch Pharm Res. 2004
- Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004
- Bianchetti A, Rozzini R, Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin. 2003
- Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev. 2003
- Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol. 2003
- De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D. 2002
- Kuratsune H, Yamaguti K, Lindh G, Evengård B, Hagberg G, Matsumura K, Iwase M, Onoe H, Takahashi M, Machii T, Kanakura Y, Kitani T, Långström B, Watanabe Y. Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage. 2002
- Dhitavat S, Ortiz D, Shea TB, Rivera ER. Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochem Res. 2002
- Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K, McClure RJ. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord. 2002
- Barrett AM. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology. 2001
- Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry. 2000
- Duru NK, Morshedi M, Schuffner A, Oehninger S. Semen treatment with progesterone and/or acetyl-L-carnitine does not improve sperm motility or membrane damage after cryopreservation-thawing. Fertil Steril. 2000
- Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology. 2000
- Famularo G, De Simone C. Treatment with acetyl-L-carnitine has the potential to improve the clinical course of painful peripheral neuropathies in HIV-positives patients. J Peripher Nerv Syst. 1998
- Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, Greco AV. Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism. 2000
- Turpeinen AK, Kuikka JT, Vanninen E, Yang J, Uusitupa MI. Long-term effect of acetyl-L-carnitine on myocardial 123I-MIBG uptake in patients with diabetes. Clin Auton Res. 2000
- [No authors listed] Acetyl-L-carnitine. Altern Med Rev. 1999
- Di Marzio L, Moretti S, D'Alò S, Zazzeroni F, Marcellini S, Smacchia C, Alesse E, Cifone MG, De Simone C. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin Immunol. 1999
- Brooks JO 3rd, Yesavage JA, Carta A, Bravi D. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr. 1998
- Ebeling P, Tuominen JA, Arenas J, Garcia Benayas C, Koivisto VA. The association of acetyl-L-carnitine with glucose and lipid metabolism in human muscle in vivo: the effect of hyperinsulinemia. Metabolism. 1997
- James JS. Drug-related neuropathy: low acetylcarnitine levels found. AIDS Treat News. 1997
- Scarpini E, Sacilotto G, Baron P, Cusini M, Scarlato G. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst. 1997
- Jackson JM, Lee HA. L-carnitine and acetyl-L-carnitine status during hemodialysis with acetate in humans: a kinetic analysis. Am J Clin Nutr. 1996
- Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, Pettegrew JW, Pfeiffer E, Raskind MA, Sano M, Tuszynski MH, Woolson RF. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996
- Jeulin C, Lewin LM. Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Hum Reprod Update. 1996
- Scarpini E, Doneda P, Pizzul S, Chiodi P, Ramacci MT, Baron P, Conti G, Sacilotto G, Arduini A, Scarlato G. L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects. J Peripher Nerv Syst. 1996
- Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Giugliano D. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia. 1995
- Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging. 1995
- Sabbá C, Berardi E, Antonica G, Ferraioli G, Buonamico P, Godi L, Brevetti G, Albano O. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur Heart J. 1994
- Van Hove JL, Kahler SG, Millington DS, Roe DS, Chace DH, Heales SJ, Roe CR. Intravenous L-carnitine and acetyl-L-carnitine in medium-chain acyl-coenzyme A dehydrogenase deficiency and isovaleric acidemia. Pediatr Res. 1994
- Forloni G, Angeretti N, Smiroldo S. Neuroprotective activity of acetyl-L-carnitine: studies in vitro. J Neurosci Res. 1994
- Carta A, Calvani M, Bravi D, Bhuachalla SN. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere. Ann N Y Acad Sci. 1993
- Portela A, Cornélissen G, Blank M, Kumagai Y, Bingham C, Bartolomucci G, Halberg F. Circadian stage-dependence of acetyl-L-carnitine effects on blood pressure and heart rate of clinically healthy subjects. Chronobiologia. 1993
- Calvani M, Carta A, Caruso G, Benedetti N, Iannuccelli M. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease. Ann N Y Acad Sci. 1992
- Grizard G, Lombard-Vignon N, Boucher D. Changes in carnitine and acetylcarnitine in human semen during cryopreservation. Hum Reprod. 1992
- Westlund KN, Lu Y, Werrbach-Perez K, Hulsebosch CE, Morgan B, Pizzo DP, Eisenberg HM, Perez-Polo JR. Effects of nerve growth factor and acetyl-L-carnitine arginyl amide on the human neuronal line HCN-1A. Int J Dev Neurosci. 1992
- Parnetti L, Gaiti A, Mecocci P, Cadini D, Senin U. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol. 1992
- Mezzina C, De Grandis D, Calvani M, Marchionni A, Pomes A. Idiopathic facial paralysis: new therapeutic prospects with acetyl-L-carnitine. Int J Clin Pharmacol Res. 1992
- Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, Tettamanti M, Frattura L, Tiraboschi P, Comelli M, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology. 1991
- Gasparetto A, Corbucci GG, De Blasi RA, Antonelli M, Bagiella E, D'Iddio S, Trevisani C. Influence of acetyl-L-carnitine infusion on haemodynamic parameters and survival of circulatory-shock patients. Int J Clin Pharmacol Res. 1991
- Carta A, Calvani M. Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer's disease? Ann N Y Acad Sci. 1991
- Jirillo E, Altamura M, Munno I, Pellegrino NM, Sabato R, Di Fabio S, De Simone C. Effects of acetyl-L-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study. Immunopharmacol Immunotoxicol. 1991
- Genazzani AD, Petraglia F, Algeri I, Gastaldi M, Calvani M, Botticelli G, Genazzani AR. Acetyl-l-carnitine as possible drug in the treatment of hypothalamic amenorrhea. Acta Obstet Gynecol Scand. 1991
- Campi N, Todeschini GP, Scarzella L. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther. 1990
- Sinforiani E, Iannuccelli M, Mauri M, Costa A, Merlo P, Bono G, Nappi G. Neuropsychological changes in demented patients treated with acetyl-L-carnitine. Int J Clin Pharmacol Res. 1990
- Arrigo A, Casale R, Buonocore M, Ciano C. Effects of acetyl-L-carnitine on reaction times in patients with cerebrovascular insufficiency. Int J Clin Pharmacol Res. 1990
- Postiglione A, Cicerano U, Soricelli A, De Chiara S, Gallotta G, Salvatore M, Mancini M. Cerebral blood flow in patients with chronic cerebrovascular disease: effect of acetyl L-carnitine. Int J Clin Pharmacol Res. 1990
- Kelly JG, Hunt S, Doyle GD, Laher MS, Carmody M, Marzo A, Arrigoni Martelli E. Pharmacokinetics of oral acetyl-L-carnitine in renal impairment. Eur J Clin Pharmacol. 1990
- Arduini A, Rossi M, Mancinelli G, Belfiglio M, Scurti R, Radatti G, Shohet SB. Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability. Life Sci. 1990
- Herrmann WM, Dietrich B, Hiersemenzel R. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome. Int J Clin Pharmacol Res. 1990
- Passeri M, Cucinotta D, Bonati PA, Iannuccelli M, Parnetti L, Senin U. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Int J Clin Pharmacol Res. 1990
- Tempesta E, Troncon R, Janiri L, Colusso L, Riscica P, Saraceni G, Gesmundo E, Calvani M, Benedetti N, Pola P. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. Int J Clin Pharmacol Res. 1990
- Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin. 1990
- Rosadini G, Marenco S, Nobili F, Novellone G, Rodriguez G. Acute effects of acetyl-L-carnitine on regional cerebral blood flow in patients with brain ischaemia. Int J Clin Pharmacol Res. 1990
- Bella R, Biondi R, Raffaele R, Pennisi G. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res. 1990
- Marzo A, Arrigoni Martelli E, Urso R, Rocchetti M, Rizza V, Kelly JG. Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers. Eur J Clin Pharmacol. 1989
- Martignoni E, Facchinetti F, Sances G, Petraglia F, Nappi G, Genazzani AR. Acetyl-L-carnitine acutely administered raises beta-endorphin and cortisol plasma levels in humans. Clin Neuropharmacol. 1988
- Cooper MB, Forte CA, Jones DA. Carnitine and acetylcarnitine in red blood cells. Biochim Biophys Acta. 1988
- Passeri M, Iannuccelli M, Ciotti G, Bonati PA, Nolfe G, Cucinotta D. Mental impairment in aging: selection of patients, methods of evaluation and therapeutic possibilities of acetyl-L-carnitine. Int J Clin Pharmacol Res. 1988
- Tempesta E, Casella L, Pirrongelli C, Janiri L, Calvani M, Ancona L. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res. 1987
- Schinetti ML, Rossini D, Greco R, Bertelli A. Protective action of acetylcarnitine on NADPH-induced lipid peroxidation of cardiac microsomes. Drugs Exp Clin Res. 1987
- Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol. 1986
- Hoppel CL, Genuth SM. Urinary excretion of acetylcarnitine during human diabetic and fasting ketosis. Am J Physiol. 1982
- Novak M, Wieser PB, Buch M, Hahn P. Acetylcarnitine and free carnitine in body fluids before and after birth. Pediatr Res. 1979
Article last updated on: March 13th, 2018 by Nootriment
8 Comments
There must be sufficient amounts of choline available in order for the acetylcholine conversion (to Acetylcholine) to occur.Following the recommended dosage of each substance, I am taking 900mg Acetyl L-carnitine and 500mg Citicoline daily. Do I need to adjust my intake of Citicoline if I am taking L-Carnitine also? What is the proper ratio?
Sometimes, I also take 600mg Alpha GPC. If I am to combine Acetyl L-Carnitine with Alpha GPC, what would be the proper ratio?
Hey Joseph,
Unfortunately, there have not been any studies that have looked at the optimal dosage of combining these two supplements. Most users will find their own optimal dosage through titration.
In my stack, I use 500 mg of ALCAR with 300 mg of Alpha GPC twice a day but this is based on personal experience.
Also, thought I would mention that since Citicoline contains less free choline per dosage than Alpha GPC, I usually use a larger dosage of Citicoline than Alpha GPC.
I hope that helps!
This site contains detailed yet easy to comprehend info. The prompt replies answer the questions in a friendly manner. I wish I can get to know the persons behind such valuable info so that I can appreciate more their work. Thank you so much in advance.
Thanks Joseph – I really appreciate that!
That’s really been the goal to provide comprehensive information but in easy to understand language :)
I’m glad you like visiting the site!
Hi there,
As Joseph stated, this site is great. Lots of great info, you are doing a great job!
I did have a question though.
You recommend that ALCAR be taken with a meal, though you say it is not necessary, is this because carbs facilitate its absorption? I have read on other sites not to take it with food or fat as it is water soluble. However many bodybuilding site recommend taking it with carbs. I realise this is probably to max the fat burning and energy producing effects. However I am more interested in it as a Nootropic.
Thank you for your help and keep up the excellent work!
Hey Nik,
Most of the studies I’ve read have administered ALCAR with meals, though to my knowledge there has not been a study comparing absorption in a fed and fasted state, or comparing absorption between consumption with carbs versus consumption with fats.
Here’s a good article that discusses ALCAR absorption: http://lpi.oregonstate.edu/mic/dietary-factors/L-carnitine#absorption
Hope that helps!
Hello: I am wondering I realize that L-Lysine is a precursor when taking with other things to ALCAR so is it okay to take L -Lysine still with the ALCAR or is that redundant. I have a connective tissue disorder and Immunue disorders so that is why I started taking L-Lysine and have been taking for awhile. I found the ALCAR recently and have brain lesions as well as cognitive issues and so ordered it not realizing all of the above. Any advice is greatly appreciated, so glad to have found this information :)
Great info! How does vitamin B5 compare to ALCAR for purposes of using together with a choline source in order to produce more Acetylcholine?